These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 3783976)
1. [Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma]. Miyauchi A; Onishi T; Matsuzuka F; Hirai K; Kuma K; Takai S; Nakamoto K; Nakamura K; Nanjo S; Maeda M Gan No Rinsho; 1986 Oct; 32(12):1519-24. PubMed ID: 3783976 [TBL] [Abstract][Full Text] [Related]
2. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times. Papapetrou PD; Polymeris A Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112 [TBL] [Abstract][Full Text] [Related]
3. [Plasma tumor markers (calcitonin and carcinoembryonic antigen) in medullary thyroid cancers]. Argémi B; Vagneur JP; Conforto C; Even F; Rollat MC; Simonin R Bull Cancer; 1984; 71(2):133-9. PubMed ID: 6733293 [TBL] [Abstract][Full Text] [Related]
4. [Evaluation of surgical results and prediction of prognosis by analysis of serum tumor marker levels: proposal of a theory tested on patients with medullary thyroid carcinoma]. Miyauchi A Gan No Rinsho; 1988 May; 34(6):739-43. PubMed ID: 3379756 [TBL] [Abstract][Full Text] [Related]
5. [Assessment of surgical treatments of medullary thyroid carcinoma by analysis of serum calcitonin levels]. Miyauchi A; Matsuzuka F; Kuma K; Takai S; Maeda M Nihon Geka Gakkai Zasshi; 1987 Jan; 88(1):102-8. PubMed ID: 3821708 [TBL] [Abstract][Full Text] [Related]
7. Correlation between calcitonin and carcinoembryonic antigen levels in medullary carcinoma of the thyroid. Calmettes C; Moudktar MS; Milhaud G Biomedicine; 1977 Mar; 27(2):52-4. PubMed ID: 861349 [TBL] [Abstract][Full Text] [Related]
8. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis. Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448 [TBL] [Abstract][Full Text] [Related]
9. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832 [TBL] [Abstract][Full Text] [Related]
10. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse]. Łacka K; Michałek K; Majewski P Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567 [TBL] [Abstract][Full Text] [Related]
11. Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: a comparative study. Hamada S; Ishikawa N; Yoshi M; Morita R; Fukunaga M Endocrinol Jpn; 1976 Dec; 23(6):505-10. PubMed ID: 1022524 [TBL] [Abstract][Full Text] [Related]
12. [Tumours markers. Calcitonin and carcinoembryonic antigen in medullary carcinoma of the thyroid (author's transl)]. Calmettes C; Moukhtar MS; Milhaud G Presse Med (1893); 1979 Dec; 8(48):3947-50. PubMed ID: 530945 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF; J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497 [TBL] [Abstract][Full Text] [Related]
14. Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Miyauchi A; Onishi T; Morimoto S; Takai S; Matsuzuka F; Kuma K; Maeda M; Kumahara Y Ann Surg; 1984 Apr; 199(4):461-6. PubMed ID: 6712322 [TBL] [Abstract][Full Text] [Related]
15. Clinical value of calcitonin and carcinoembryonic antigen doubling times in medullary thyroid carcinoma. Jackson CE; Norum RA; Talpos GB; Feldkamp CS; Tashjian AH Henry Ford Hosp Med J; 1987; 35(2-3):120-1. PubMed ID: 2891643 [No Abstract] [Full Text] [Related]
16. The use of octreotide in the treatment of medullary thyroid carcinoma. Frank-Raue K; Ziegler R; Raue F Horm Metab Res Suppl; 1993; 27():44-7. PubMed ID: 8330871 [TBL] [Abstract][Full Text] [Related]
17. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma. Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443 [TBL] [Abstract][Full Text] [Related]
18. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy. Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. Saad MF; Fritsche HA; Samaan NA J Clin Endocrinol Metab; 1984 May; 58(5):889-94. PubMed ID: 6707192 [TBL] [Abstract][Full Text] [Related]
20. Recent results of reoperative surgery in medullary carcinoma of the thyroid. Tisell LE; Jansson S Wien Klin Wochenschr; 1988 May; 100(11):347-8. PubMed ID: 3407193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]